Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data

• DOI: 10.1371/journal.pone.0163567
• Publication Date: 2016-09-30T17:27:49Z
• Authors: Koen B. Pouwels; Sefika E. Bozdemir; Selen Yegenoglu; Solmaz Celebi; E. David McIntosh; Serhat Unal; Maarten J. Postma; Mustafa Hacimusta...
• Keywords: Mass vaccination

Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of morbidity and mortality among infants young children. Although no active vaccine available on market yet, there are several development programs in various stages. To assess whether one these vaccines might a future asset for national immunization programs, modeling costs benefits vaccination strategies needed.To evaluate potential cost-effectiveness RSV and/or pregnant women Turkey.A multi-cohort static Markov model with cycles month was used compare vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort divided by twelve construct monthly equal size (111,459 new-borns). Model input based clinical data from multicenter prospective study Bursa, Turkey, combined figures (inter)national literature publicly Statistical Institute (TÜÏK). Incremental ratios (ICERs) were expressed Lira (TL) per quality-adjusted life year (QALY) gained.Vaccinating at 2 4 months age would prevent 145,802 GP visits, 8,201 hospitalizations 48 deaths during first life, corresponding total gain 1650 QALYs. discounted ICER estimated 51,969 TL (26,220 US $ 2013) QALY gained. Vaccinating both more cases, but less attractive pure economic point view 61,653 (31,106 QALY. only pregnancy result fewer cases prevented than infant favorable ICER.RSV has cost-effective Turkey. using relatively conservative assumptions, all evaluated remained slightly below threshold 3 times GDP capita.